Mar 15, 2023 / 06:40PM GMT
Mark Breidenbach - Oppenheimer & Co. Inc. - Analyst
Right. Hi, everyone. Thanks so much again for joining us on day three of Oppenheimer's 33rd Annual Healthcare Conference. My name is Mark Breidenbach. I'm one of the research analysts here at Oppenheimer.
And the final presenting company here for today is Olema Pharmaceuticals, which is developing OP-1250, a novel endocrine receptor targeted medicine for ER-positive/HER2-negative breast cancer. Joining us to walk us through the story is the company's President and CEO, Sean Bohen. (Operator Instructions) And with that said, let's dive right into the presentation. Sean, the mic is yours.
Sean Bohen - Olema Pharmaceuticals, Inc. - President & CEO
Thank you very much, Mark. And thank you, everyone, at the end of a long day for those of you participating, for taking the time to learn about Olema and hanging in there with us.
So Olema is a company that is based on advancing therapies for cancers occurring primarily in women. And as Mark mentioned, our lead molecule, our sole clinical
Olema Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 15, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers